JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2017, Vol. 55 ›› Issue (4): 82-85.doi: 10.6040/j.issn.1671-7554.0.2016.283

Previous Articles     Next Articles

In vitro synergy testing of sitafloxacin, cefoperazone-sulbactam and polymyxin E against extensively drug-resistant Acinetobacter baumannii

LI An, CHEN Fengzhe, WANG Zheng, MENG Xiangzhu, XU Nannan, MA Lixian   

  1. Department of Infectious Diseases, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Received:2016-03-15 Online:2017-04-10 Published:2017-04-10

PDF (PC)

182

Abstract: Objective To evaluate the in vitro activities of sitafloxacin, cefoperazone-sulbactam(1∶1)and polymyxin E used alone or in combination against extensively drug-resistant Acinetobacter baumannii (XDR-A. baumannii). Methods A total of 22 strains of XDR-A. baumannii were isolated from clinical patients. The minimum inhibitory concentration(MIC)values of sitafloxacin, cefoperazone-sulbactam(1∶1), and polymyxin E used alone against XDR-A. baumannii were determined by broth microdilution method, and the MIC of drugs used in combination were determined by the checkerboard method. According to the MICs results, the values of fractional inhibitory concentration(FIC)and FIC index(FICI)were calculated. Results The MIC of sitafloxacin, cefoperazone-sulbactam(1∶1), and polymyxin E used alone was 0.25-16, 4.0/4.0-128/128, and 0.5-8.0 μg/mL, respectively. When two drugs were used in combination, all of the MICs were decreased. Conclusion Most combinations of the three drugs were synergy, partial synergy or additive when compared to the drugs used alone.

Key words: Extensively drug-resistant Acinetobacter baumannii, Polymyxin E, Combinations, Sitafloxacin, Cefoperazone-sulbactam

CLC Number: 

  • R378.99
[1] Cerqueira GM, Peleg AY. Insights into Acinetobacter baumannii pathogenicity[J]. IUBMB life, 2011, 63(12):1055-1060.
[2] Howard A, ODonoghue M, Feeney A. Acinetobacter baumannii: an emerging opportunistic pathogen[J]. Virulence, 2012, 3(3):243-250.
[3] Liu WP, Tian YQ, Hai YT, et al. Prevalence survey of nosocomial infections in the Inner Mongolia Autonomous Region of China[2012-2014] [J]. J Thorac Dis, 2015, 7(9):1650-1657.
[4] 陈佰义, 何礼贤, 胡必杰, 等. 中国鲍曼不动杆菌感染诊治与防控专家共识[J]. 中华医学杂志, 2012, 92(2):76-85.
[5] Roca I, Espinal P, Vila-Farrés X, et al. The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drug-resistant menace[J]. Front Microbiol, 2012, 3:148. doi:10.3389/fmicb.2012.00148. eCollection, 2012.
[6] Magiorakos AP, Srinivasan A, Carey RB. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance[J]. Clin Microbiol Infect, 2012, 18(3): 268-281.
[7] CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement: CLSI Document M100-S25[S]. Wayne. PA: Clinical and Laboratory Standards Institute, 2015. http://www.clsi.org.
[8] Thamlikitkul V, Tiengrim S. In vitro activity of sitafloxacin against carbapenem-resistant Acinetobacter baumannii[J]. Int J Antimicrob Agents, 2013, 42(3): 284-285.
[9] European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0[EB/OL].(2015-01-01)[2016-03-15]. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_5.0_Breakpoint_Table_01.pdf
[10] Kiffer CR, Sampaio JL, Sinto S, et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii[J]. Diagn Microbiol Infect Dis, 2005, 52(4):317-322.
[11] Alfandari S, Gois J, Delannoy PY, et al. Management and control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit[J]. Med Mal Infect, 2014, 44(5):229-231.
[12] Ayraud-Thévenot S, Huart C, Mimoz O, et al. Control of multi-drug-resistant Acinetobacter baumannii outbreaks in an intensive care unit: feasibility and economic impact of rapid unit closure[J]. J Hosp Infect, 2012, 82(4):290-292.
[13] Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia[J]. Int J Antimicrob Agents, 2011, 37(4):291-295.
[14] Bean DC, Wigmore SM. Antibiotic tolerance and combination therapy[J]. MBio, 2015, 6(2):e00120. doi: 10.1128/mBio.00120-15.
[15] Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options[J]. Int J Antimicrob Agents, 2012, 39(2):105-114.
[16] Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections[J]. Drugs, 2014, 74(12):1315-1333.
[17] Huang YS, Wang JT, Sheng WH, et al. Comparative in vitro activity of sitafloxacin against bacteremic isolates of carbapenem resistant Acinetobacter baumannii complex[J]. J Microbiol Immunol Infect, 2015,48(5): 545-551.
[1] WANG Yan1, DOU Heng-li2, HU Cheng-jin1. Construction and expression of a prokaryotic vector encoding outer membrane protein OprF of Pseudomonas aeruginosa [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(9): 34-39.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd